Where AI Should Actually Earn Its Keep in Biopharma - with Mukhtar Ahmed of Greenstone Biosciences

AI in Business by Daniel Faggella

In biopharma R&D, AI investment has overwhelmingly targeted generating more drug candidates, even though the industry has rarely lacked for compounds worth pursuing. In this episode, Mukhtar Ahmed, Director of Project an...View more